NASDAQ:HCM HUTCHMED (HCM) Stock Price, News & Analysis $16.09 -0.03 (-0.19%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$15.97 -0.12 (-0.75%) As of 10/3/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About HUTCHMED Stock (NASDAQ:HCM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HUTCHMED alerts:Sign Up Key Stats Today's Range$15.98▼$16.2850-Day Range$14.83▼$19.2152-Week Range$11.51▼$21.50Volume68,187 shsAverage Volume55,356 shsMarket Capitalization$2.81 billionP/E RatioN/ADividend YieldN/APrice Target$20.88Consensus RatingHold Company Overview HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market. HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer. Its clinical pipeline features both small molecules and monoclonal antibodies targeting receptor tyrosine kinases, immuno-oncology checkpoints and novel pathways, with ongoing trials in the United States, Europe and Asia. The company has established strategic partnerships and licensing collaborations with leading global pharmaceutical and biotechnology firms to co-develop and co-commercialize its assets. Founded in 2000 as Hutchison MediPharma and rebranded as HUTCHMED in 2018, the company is headquartered in Hong Kong, with research and development centers in Shanghai and Suzhou, China. HUTCHMED maintains commercial operations across mainland China and extends its clinical research infrastructure to the United States and Europe. Guided by an experienced leadership team with backgrounds in drug discovery, clinical development and commercial strategy, HUTCHMED continues to pursue its goal of delivering innovative medicines to patients worldwide.AI Generated. May Contain Errors. Read More HUTCHMED Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreHCM MarketRank™: HUTCHMED scored higher than 42% of companies evaluated by MarketBeat, and ranked 680th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingHUTCHMED has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Upside PotentialHUTCHMED has a consensus price target of $20.88, representing about 29.7% upside from its current price of $16.09.Amount of Analyst CoverageHUTCHMED has only been the subject of 4 research reports in the past 90 days.Read more about HUTCHMED's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth812.50% Earnings GrowthEarnings for HUTCHMED are expected to grow by 812.50% in the coming year, from $0.16 to $1.46 per share.Price to Book Value per Share RatioHUTCHMED has a P/B Ratio of 3.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.24% of the outstanding shares of HUTCHMED have been sold short.Short Interest Ratio / Days to CoverHUTCHMED has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in HUTCHMED has recently increased by 3.00%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHUTCHMED does not currently pay a dividend.Dividend GrowthHUTCHMED does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.24% of the outstanding shares of HUTCHMED have been sold short.Short Interest Ratio / Days to CoverHUTCHMED has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in HUTCHMED has recently increased by 3.00%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for HUTCHMED this week, compared to 3 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, HUTCHMED insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of HUTCHMED is held by insiders.Percentage Held by InstitutionsOnly 8.82% of the stock of HUTCHMED is held by institutions.Read more about HUTCHMED's insider trading history. Receive HCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HCM Stock News HeadlinesHUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025October 1 at 8:00 PM | globenewswire.comReviewing HUTCHMED (NASDAQ:HCM) & CollPlant Biotechnologies (NASDAQ:CLGN)September 29, 2025 | americanbankingnews.comGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks say this is just the beginning... Because there's mounting evidence that a 40% market crash could be on the way.October 4 at 2:00 AM | Stansberry Research (Ad)Morgan Stanley Downgrades HUTCHMED (HCM)September 23, 2025 | msn.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Zymeworks (ZYME), HUTCHMED (HCM) and Zai Lab (ZLAB)September 14, 2025 | theglobeandmail.comHutchmed rises 10.4%September 12, 2025 | msn.comSave the Date: HUTCHMED to Present R&D Updates on October 31, 2025September 11, 2025 | globenewswire.comHUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025September 4, 2025 | globenewswire.comSee More Headlines HCM Stock Analysis - Frequently Asked Questions How have HCM shares performed this year? HUTCHMED's stock was trading at $14.41 on January 1st, 2025. Since then, HCM stock has increased by 11.7% and is now trading at $16.09. When did HUTCHMED IPO? HUTCHMED (HCM) raised $100 million in an initial public offering (IPO) on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities served as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers. How do I buy shares of HUTCHMED? Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HUTCHMED own? Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), GE Aerospace (GE) and ServiceNow (NOW). Company Calendar Today10/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HCM CIK1648257 Webwww.chi-med.com Phone852-2121-3888Fax852-2128-1778Employees1,811Year Founded2000Price Target and Rating Average Price Target for HUTCHMED$20.88 High Price Target$28.00 Low Price Target$13.75 Potential Upside/Downside+29.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.05 Current Ratio4.65 Quick Ratio4.51 Sales & Book Value Annual Sales$602.20 million Price / Sales4.66 Cash Flow$0.29 per share Price / Cash Flow56.12 Book Value$4.43 per share Price / Book3.63Miscellaneous Outstanding Shares174,422,000Free Float168,143,000Market Cap$2.81 billion OptionableNot Optionable Beta0.45 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:HCM) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredLost Decade warning – do this nowWith the Magnificent 7 trading at bubble-like valuations, another “Lost Decade” could be looming — but Porter ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.